Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
about
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyRestoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.Oral Administration of Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects
P2860
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@ast
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@en
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@nl
type
label
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@ast
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@en
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@nl
prefLabel
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@ast
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@en
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@nl
P2093
P2860
P3181
P356
P1476
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
@en
P2093
Jahnavi Gollamudi
Jenny G Parvani
Shaveta Vinayak
William P Schiemann
P2860
P3181
P356
10.2147/CMAR.S55279
P407
P577
2016-01-01T00:00:00Z